Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.68 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106119 | 0.88 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL5113138 | 0.87 | TLR8 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL8122384 | 0.85 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| SCHEMBL4867497 | 0.85 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL6105673 | 0.84 | TLR8 (0.81) | TLR7TLR8NUDT1 | |
| SCHEMBL1892155 | 0.84 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL9602615 | 0.84 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL6106679 | 0.83 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL6106596 | 0.83 | TLR7 (0.77) | TLR7TLR8 | |
| SCHEMBL6106439 | 0.82 | TLR7 (0.63) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| EP-4419112-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | Ohio State Innovation Foundation (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118475357-A | Immunotherapy for the treatment of cancer | 俄亥俄州创新基金会 | 2024-08-09 | — | — | CN | disclosed |
| CN-110234401-B | Methods and compositions for adaptive immunomodulation | 德克萨斯大学系统董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023070132-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3294295-B1 | TLR7 AND/OR TLR8 AGONISTS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INST NAT SANTE RECH MED (FR) | 2021-08-04 | — | — | EP | disclosed |
| US-6989389-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-01-24 | — | — | US | disclosed |
| US-6953804-B2 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6677348-B2 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6670372-B2 | Immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of viral and neoplastic diseases; imidazo(4,5-c) quinoline-4-amine compounds that have an ether containing substituent at the 1-position | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1341789-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138248-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR7 20/4885TLR8 68/4885NUDT1 1242/4885 |
| US-20040106640-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR7 20/4885TLR8 68/4885NUDT1 1242/4885 |
| US-20030212092-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR7 20/4885TLR8 68/4885NUDT1 1242/4885 |
| US-20030212091-A1 | Aryl ether substituted imidazoquinolines | IRF3, IFNG, MYD88 | TLR7 20/4885TLR8 68/4885NUDT1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.